Chronic Idiopathic Urticaria

>

The HCPLive chronic idiopathic urticaria page is a comprehensive resource for clinical news and insights on CIU. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Latest News

Close-up image of a person itching their hand. | Credit: Pexels
LIBERTY-CUPID Study C Confirms Benefit of Dupilumab in Biologic-Naive CSU

September 15th 2024

Dupilumab reduced itch and disease activity in patients with uncontrolled CSU, confirming prior findings from the LIBERTY-CUPID program in a phase 3 trial.

FDA Approves Add-On Dupilumab for Chronic Spontaneous Urticaria
Regeneron, Sanofi Receive CRL for Add-On Dupilumab sBLA for Chronic Spontaneous Urticaria

October 20th 2023

Ligelizumab Improves Sleep and Disease Burden in CSU Patients
Ligelizumab Improves Sleep and Disease Burden in CSU Patients

March 1st 2022

Overlapping Eosinophilic Diseases Linked to Greater Disease Burden in EoE Patients
Overlapping Eosinophilic Diseases Linked to Greater Disease Burden in EoE Patients

February 28th 2022

BTK-Inhibition Considered for Dermatologic Conditions
BTK-Inhibition Considered for Dermatologic Conditions

February 21st 2022

More News

What Can Pathophysiology Tell Us about the Management of Chronic Urticaria?

March 3rd 2014

Research shows that although mast cells are key effector cells in the pathogenesis of urticaria, targeting individual mast cell mediators is often not therapeutically effective

<123
© 2024 MJH Life Sciences

All rights reserved.